In this episode of the Pillr Unpacked podcast, Sumona discusses UW Medicine's new initiative to highlight the impact of the 340B program and share the multifaceted benefits of 340B in enhancing patient care and community health. She explains how the initiative was structured, the role of the 340B oversight committee, and the importance of creating a consistent narrative to share with various stakeholders. This initiative has allowed UW Medicine to showcase the significant benefits of the 340B program, such as providing substantial financial assistance for prescriptions, supporting specialized clinics for vulnerable populations, and enhancing overall patient outcomes. We invite you to learn from Sumona's first-hand experience and reach out to her with any questions as you consider rolling out similar initiatives at your Covered Entity.

In this podcast episode, we are joined by Ted Slafsky, Publisher and CEO of the 340B Report and Founder & Principal of Wexford Solutions LLC.

During our discussion, Ted highlights ongoing federal court decisions and updates listeners on states like Arkansas and Louisiana, where laws restoring 340B pricing have faced legal challenges but are making progress. We also cover a recent and pressing topic - the "Sustain 340B Act," a draft senate bill addressing various aspects of the program, including contract pharmacy restrictions and patient definition. Additionally, Ted discusses the significance of Senator John Thune's involvement in the bill, and how changes in Senate leadership have the potential to impact the program's future.

In this episode of the Pillr Unpacked podcast, hosts Jonathan Ghenn and Rhodie Smith engage in a conversation with Rob Johnson, a pharmacist and entrepreneur who founded RPh Innovations, a company providing professional support services to 340B covered entities.

Rob shares insight into the evolving dynamics of the 340B program over his years of experience, highlighting the increasing complexity, especially with manufacturer blocks. The discussion delves into the value RPHi brings to covered entities, focusing on areas such as price file verifications, eligibility, and optimizing savings potential. Rob also addresses the challenges around in-house pharmacies and shares his perspective on the future of the 340B program.